Abrocitinib

阿布昔替尼

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameAbrocitinib
Drug Alias Name阿布罗替尼JAK 1 inhibitor (Pfizer)CibinqoCIBINQO希必可 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsPlaque psoriasisPrurigo NodularisPost-Acute COVID-19 Syndrome +[22] 
Global Approved IndicationsDermatitis, Atopic
Approved Indications in ChinaDermatitis, Atopic
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2021/09/09
Country/TerritoryCzechiaBelgiumBulgaria +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (China) Research And Development Co LtdPharmacia & Upjohn Company LlcYale University +[11] 
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisPost-Acute COVID-19 SyndromeFatigue +[12] 
Inactive IndicationsPlaque psoriasisHypersensitivity, ImmediateHypersensitivity +[10] 

Other Information

ATC CodeD11A
Related LinksWikipediaDrugBankKEGG